A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Journal of acquired immune deficiency syndromes (1999)

Volumn 61, Issue 3, 2012, Pages 317-325

  Hatano, Hiroyu ^a   Scherzer, Rebecca ^b   Wu, Yuaner ^b   Harvill, Kara ^b   Maka, Kristinalisa ^b   Hoh, Rebecca ^b   Sinclair, Elizabeth ^b   Palmer, Sarah ^b   Martin, Jeffrey N ^b   Busch, Michael P ^b   Deeks, Steven G ^b   Hsue, Priscilla Y ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR; RALTEGRAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; VASODILATION; VIRAL LOAD;

EID: 85027920222     PISSN: None     EISSN: 19447884     Source Type: Journal    
DOI: 10.1097/qai.0b013e31826e7d0f     Document Type: Article

References (0)